Worth reading
60In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
60.1
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSNet Sales311,810¥ millionYear on year +19.9%Progress 25.2%
Operating profit89,480¥ millionYear on year +60.1%Progress 34.7%
Ordinary income90,321¥ millionYear on year +63.5%
Net income attributable to owners of the parent70,426¥ millionYear on year +68.3%Progress 36.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥47.74
Financial position at period-end
Total assets2,374,093¥ million
of which net assets 1,662,023 ¥ millionEquity ratio 70.0%vs. prior year-end +1.5pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+74,478
Investment-28,273
Financials-16,191
Net change+30,014
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥314,633 million
Segment revenueCardiovascular Company ¥188,141 million (YoY +19.2%), Medical Care Solutions Company ¥56,587 million (YoY +12.3%), Blood and Cell Technologies Company ¥60,776 million (YoY +17.7%), Organ Technologies Business ¥6,225 million
Segment profitCardiovascular Company ¥59,971 million, Medical Care Solutions Company ¥7,076 million, Blood and Cell Technologies Company ¥11,135 million, Organ Technologies Business ¥940 million
Regional sales¥126,140 million (YoY +25.5%), ¥67,389 million (YoY +24.1%), ¥27,955 million (YoY +21.9%), ¥35,558 million (YoY +20.9%), ¥257,044 million (YoY +24.1%), ¥54,765 million (YoY +3.7%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥1,239,000 million (YoY +9.5%)
Operating profit¥257,500 million (YoY +46.0%)
Ordinary incomeNot disclosed
Net income¥193,100 million (YoY +42.1%)
Revision to Earnings ForecastRevenue Not disclosed → ¥1,239,000 million / Operating profit Not disclosed → ¥257,500 million / Profit for the period attributable to owners of the parent Not disclosed → ¥193,100 million
Annual Dividend Forecast¥30 → ¥36（+20.0%）
Factors Behind Changes in Business Performance
Sales remained strong as global demand for healthcare expanded and foreign exchange movements also contributed. The increase in revenue and the refund of U.S. tariffs were the main factors behind the increase in gross profit, while the increase in gross profit and the recording of settlement proceeds received were the main factors behind the increase in operating profit and other profit items.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Material subsequent eventsOn 24 July 2026, the payment date, the company issued ¥40 billion in Series 12 unsecured corporate bonds. The proceeds will be used to repay borrowings.
Impairment lossNo impairment loss was recorded for the period (shown as "—" in the statement of cash flows).
Breakdown of extraordinary income (loss)Temporary gains and losses Settlement proceeds received ¥20,110 million, Expensing of the inventory step-up associated with the acquisition of OrganOx ¥2,561 million
Depreciation and amortization¥27,190 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for securities analysts and institutional investors)
Issued Shares at Period-End1,480,559,680
Treasury Shares at Period-End5,458,187
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥311,810 million (YoY +19.9%) |
| Operating profit | ¥89,480 million (YoY +60.1%) |
| Ordinary income | ¥90,321 million (YoY +63.5%) |
| Profit attributable to owners of the parent | ¥70,426 million (YoY +68.3%) |
| Net income per share | ¥47.74 |
| Equity ratio | End of the current fiscal period 70 / End of previous period 68.5 |
| Total assets | ¥2,374,093 million |
| Net assets | ¥1,662,023 million |
| Cash flows from operating activities | ¥74,478 million |
| Cash flows from investing activities | ¥-28,273 million |
| Cash flows from financing activities | ¥-16,191 million |
| Cash and cash equivalents at end of period | ¥314,633 million |
| Full-year earnings forecast | Net Sales ¥1,239,000 million (YoY +9.5%) / Operating profit ¥257,500 million (YoY +46.0%) / Ordinary income Not disclosed / Net income ¥193,100 million (YoY +42.1%) |
| Revision to Earnings Forecast | Revenue Not disclosed → ¥1,239,000 million / Operating profit Not disclosed → ¥257,500 million / Profit for the period attributable to owners of the parent Not disclosed → ¥193,100 million |
| Annual Dividend Forecast | ¥30 → ¥36（+20.0%） |
| Segment revenue | Cardiovascular Company ¥188,141 million (YoY +19.2%), Medical Care Solutions Company ¥56,587 million (YoY +12.3%), Blood and Cell Technologies Company ¥60,776 million (YoY +17.7%), Organ Technologies Business ¥6,225 million |
| Segment profit | Cardiovascular Company ¥59,971 million, Medical Care Solutions Company ¥7,076 million, Blood and Cell Technologies Company ¥11,135 million, Organ Technologies Business ¥940 million |
| Regional sales | ¥126,140 million (YoY +25.5%), ¥67,389 million (YoY +24.1%), ¥27,955 million (YoY +21.9%), ¥35,558 million (YoY +20.9%), ¥257,044 million (YoY +24.1%), ¥54,765 million (YoY +3.7%) |
| Depreciation and amortization | ¥27,190 million |
| Impairment loss | No impairment loss was recorded for the period (shown as "—" in the statement of cash flows). |
| Breakdown of extraordinary income (loss) | Temporary gains and losses Settlement proceeds received ¥20,110 million, Expensing of the inventory step-up associated with the acquisition of OrganOx ¥2,561 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | On 24 July 2026, the payment date, the company issued ¥40 billion in Series 12 unsecured corporate bonds. The proceeds will be used to repay borrowings. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 1,480,559,680 |
| Treasury Shares at Period-End | 5,458,187 |
| Factors Behind Changes in Business Performance | Sales remained strong as global demand for healthcare expanded and foreign exchange movements also contributed. The increase in revenue and the refund of U.S. tariffs were the main factors behind the increase in gross profit, while the increase in gross profit and the recording of settlement proceeds received were the main factors behind the increase in operating profit and other profit items. |
Items this document does not state (4)
Operating MarginPayout ratioShareholder Return PolicyOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Global demand for healthcare expanded and foreign exchange movements also contributed, while a refund of U.S. tariffs and settlement proceeds received were recorded.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.